Quadruple Marker Test

The Quadruple Marker is a highly recommended prenatal screening prescribed by healthcare professionals to pregnant women between weeks 15–22 of their pregnancy. The blood test helps assess the risk of chromosomal abnormalities developing in the fetus such as Down syndrome (Trisomy 21) and Edward syndrome (Trisomy 18) as well as neural tube defects.

Quadruple Marker Test

The blood test measures the level of four specific substances which exist in maternal blood o assess the potential risk of birth defects or genetic conditions:

• Alpha-fetoprotein (AFP) – a protein produced by the fetal liver
• Human Chorionic Gonadotropin (hCG) – pregnancy hormone produced by the placenta
• Unconjugated Estriol (uE3) – an estrogen generated by both the fetus and placenta
• Inhibin-A – a hormone related to pregnancy

An irregular level of these substances in maternal blood may indicate higher risk of birth defects or chromosomal abnormalities. The test operates as a screening tool but it does not offer a conclusive diagnosis, and further tests may be advised.

The Quadruple Marker test is recommended for :

• Women over age 35 or those with a family history of genetic conditions
• Patients who missed first trimester screenings
• Women undergoing IVF or high-risk pregnancies

The Quadruple Marker test is available today at UniQ Pathlab, offering free home sample collection and fast report turnaround to support your pregnancy health planning.